Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes

Simple item page
dc.article.number102565
dc.catalogadorpva
dc.contributor.authorCiampi, Ethel
dc.contributor.authorUribe San Martín, Reinaldo
dc.contributor.authorSoler León, Bernardita María
dc.contributor.authorMolnar, Karolyn
dc.contributor.authorReyes Placencia, Diego Armando
dc.contributor.authorKeller Matamala, Karina Pascale
dc.contributor.authorCárcamo Rodríguez, Claudia Andrea
dc.date.accessioned2024-01-12T16:59:35Z
dc.date.available2024-01-12T16:59:35Z
dc.date.issued2020
dc.description.abstractBackground: Comorbidities are prevalent among Multiple Sclerosis (MS) patients. Few studies have characterized their prevalence and impact in Latin American populations.Objective: We aim to assess the prevalence of comorbidities and their impact on the risk of physical disability across different MS phenotypes.Methods: Cross-sectional multicenter study of patients under regular clinical care at the Programa de Esclerosis Múltiple UC and Hospital Dr. Sótero del Río in Chile. Prevalence of comorbidities was estimated from the retrospective assessment of electronic medical charts. Disease phenotypes were categorized into two groups: clinically isolated syndrome/relapsing-remitting (inflammatory group) and primary/secondary progressive MS patients (progressive group). A multivariable analysis using binary logistic regression for assessing the risk of EDSS ≥ 6.0 in each group was performed.Results: A total of 453 patients was included, 71% female, mean age at onset 31 years, mean disease duration 10 years, and median EDSS 2.0 (range 0–10). In the whole sample, most prevalent comorbidities were ever-smoking (42.2%), depression/anxiety (34.9%), thyroid disease (15.7%), hypertension (11.3%) and insulin resistance/type 2 diabetes mellitus (11.0%). When assessing the risk of EDSS ≥ 6, in the inflammatory group (N = 366), age at onset (OR 1.06, 95%CI(1.02–1.11), p = 0.008), disease duration (OR 1.06, 95%CI(1.00–1.12), p = 0.039) and epilepsy comorbidity (OR 5.36, 95%CI(1.33–21.5), p = 0.018) were associated with a higher risk of disability. In the progressive group (N = 87), disease duration was a risk factor (OR 1.08 95%CI(1.02–1.16), p = 0.014), while shorter diagnostic delay (OR 0.91 95%CI(0.85–0.99), p = 0.025) and insulin resistance/type 2 diabetes mellitus comorbidity were protective factors (OR 0.18 95%CI(0.04–0.83), p = 0.028), 72% of these patients were receiving metformin.Conclusions: Comorbidities are common across different MS disease phenotypes. Epilepsy seems particularly related with a higher risk of physical disability in relapsing-remitting patients, while the role of insulin resistance/type 2 diabetes mellitus or the impact of metformin use as a protective factor should be further studied. Prospective and larger studies are still needed in order to assess the real impact of comorbidities and their management in MS outcomes.
dc.description.funderPropio
dc.fechaingreso.objetodigital2024-01-12
dc.fuente.origenHistorial Académico
dc.identifier.citationEthel Ciampi, Reinaldo Uribe-San-Martin, Bernardita Soler, Karolyn Molnar, Diego Reyes, Karina Keller, Claudia Càrcamo. Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes. Multiple Sclerosis And Related Disorders. 2020;46(5):1-1.
dc.identifier.doi10.1016/j.msard.2020.1025
dc.identifier.eissn2211-0356
dc.identifier.issn2211-0348
dc.identifier.scopusid000597310700016
dc.identifier.urihttps://doi.org/10.1016/j.msard.2020.102565
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80447
dc.identifier.wosidWOS:000597310700016
dc.information.autorucEscuela de Medicina; Uribe San Martín, Reinaldo ; 0000-0002-3422-7962; 127201
dc.information.autorucEscuela de Medicina; Ciampi, Ethel; 0000-0002-7330-5433; 132794
dc.information.autorucEscuela de Medicina; Soler León, Bernardita María; 0000-0002-8143-4497; 189547
dc.information.autorucEscuela de Medicina; Molnar, Karolyn; S/I; 205625
dc.information.autorucEscuela de Medicina; Reyes Placencia, Diego Armando; 0000-0001-6371-3516; 194184
dc.information.autorucEscuela de Medicina; Keller Matamala, Karina Pascale; S/I; 247648
dc.information.autorucEscuela de Medicina; Cárcamo Rodríguez, Claudia Andrea; 0000-0002-9430-216X; 562
dc.issue.numero5
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final1
dc.pagina.inicio1
dc.revistaMultiple Sclerosis and Related Disorders
dc.rightsacceso restringido
dc.subjectMultiple sclerosises_ES
dc.subjectComorbidityes_ES
dc.subjectPrevalencees_ES
dc.subjectDisabilityes_ES
dc.subjectPhenotypees_ES
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypeses_ES
dc.typecarta al editor
dc.volumen46
sipa.codpersvinculados127201
sipa.codpersvinculados132794
sipa.codpersvinculados189547
sipa.codpersvinculados205625
sipa.codpersvinculados194184
sipa.codpersvinculados247648
sipa.codpersvinculados562
sipa.trazabilidadHistorial Académico;09-07-2021
sipa.trazabilidadConveris;20-07-2021
sipa.trazabilidadORCID;2024-01-08
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence of comorbidities in Multiple Sclerosis.pdf
Size:
74.96 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas